Vumerity
E24937
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
Observed surface forms (1)
| Surface form | Occurrences |
|---|---|
| diroximel fumarate | 2 |
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
multiple sclerosis therapy
ⓘ
pharmaceutical drug ⓘ prescription medication ⓘ |
| belongsToRegimenType | disease-modifying therapy for multiple sclerosis ⓘ |
| brandOf |
Vumerity
self-linksurface differs
ⓘ
surface form:
diroximel fumarate
|
| chemicallyRelatedTo | dimethyl fumarate ⓘ |
| commonAdverseEffect |
abdominal pain
ⓘ
diarrhea ⓘ flushing ⓘ nausea ⓘ |
| contraindicatedIn |
known hypersensitivity to dimethyl fumarate
ⓘ
known hypersensitivity to diroximel fumarate ⓘ |
| developedBy |
Alkermes
ⓘ
Biogen ⓘ |
| FDAApprovalYear | 2019 ⓘ |
| foodEffect |
may be taken with or without food
ⓘ
taking with food may reduce flushing ⓘ |
| hasAdministrationFrequency | twice daily ⓘ |
| hasDosageForm | delayed-release capsule ⓘ |
| hasGenericName |
Vumerity
self-linksurface differs
ⓘ
surface form:
diroximel fumarate
|
| hasInitialDoseRegimen | lower dose for first 7 days ⓘ |
| hasMaintenanceDoseRegimen | higher dose after first week ⓘ |
| hasMechanismOfAction |
fumarate derivative
ⓘ
thought to activate the Nrf2 pathway ⓘ |
| hasPharmacologicClass |
fumaric acid ester
ⓘ
immunomodulator ⓘ |
| hasPregnancyCategory | risk not ruled out ⓘ |
| hasRegulatoryApproval |
Food and Drug Administration
ⓘ
surface form:
U.S. Food and Drug Administration
|
| hasRouteOfAdministration | oral ⓘ |
| hasRouteWarning | do not crush, chew, or sprinkle capsule contents ⓘ |
| hasTherapeuticGoal |
reduce MRI lesion activity in multiple sclerosis
ⓘ
reduce relapse rate in multiple sclerosis ⓘ slow disability progression in multiple sclerosis ⓘ |
| indicatedFor |
active secondary progressive multiple sclerosis
ⓘ
clinically isolated syndrome ⓘ relapsing forms of multiple sclerosis ⓘ relapsing-remitting multiple sclerosis ⓘ |
| indicatedPopulation | adults ⓘ |
| isTakenWith | water ⓘ |
| marketedBy | Biogen ⓘ |
| metabolizedTo | monomethyl fumarate ⓘ |
| requiresMonitoring |
liver function tests
ⓘ
lymphocyte counts ⓘ |
| seriousAdverseEffect |
liver injury
ⓘ
lymphopenia ⓘ progressive multifocal leukoencephalopathy ⓘ |
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
diroximel fumarate
this entity surface form:
diroximel fumarate